Overview
The marketing authorisation for LeukoScan has been withdrawn at the request of the marketing authorisation holder.
Product information
Latest procedure affecting product information: IAIN/0024/G
18/01/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- LeukoScan
- Active substance
- sulesomab
- International non-proprietary name (INN) or common name
- sulesomab
- Therapeutic area (MeSH)
- Osteomyelitis
- Radionuclide Imaging
- Anatomical therapeutic chemical (ATC) code
- VO4D
Pharmacotherapeutic group
Diagnostic agentsTherapeutic indication
This medicinal product is for diagnostic use only.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.
This page was last updated on